Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Keating

Showing results (851-860 of 1,115) with videos related to

Pageof 112
Sort By:
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Cancer|July 22, 2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensPhilip A Thompson, Susan M O'Brien, William G Wierda, et al.
Molecular Pharmacology|August 19, 2007
Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin IIAnnie Quan, Andrew B McGeachie, Damien J Keating, et al.
The Journal of Cell Biology|December 13, 2006
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanismHélène Pelicano, Rui-Hua Xu, Min Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patientsC L Shapiro, L Ayash, I J Webb, et al.
The American Journal of Medicine|May 1, 1986
Acute promyelocytic leukemia. M.D. Anderson Hospital experienceH M Kantarjian, M J Keating, R S Walters, et al.
Oncogene|April 12, 2016
Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexilineP-P Liu, J Liu, W-Q Jiang, et al.
Blood|February 15, 2003
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemiaHelen McCarthy, William G Wierda, Lynn L Barron, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemiaB D Cheson, P A Cassileth, D R Head, et al.
Pageof 112

Showing results (851-860 of 1,115) with videos related to

Sort By:
Pageof 112
Experimental Hematology|January 17, 2004
Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survivalIssa F Khouri, Ming-Sheng Lee, Rima M Saliba, et al.
Cancer|July 22, 2015
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensPhilip A Thompson, Susan M O'Brien, William G Wierda, et al.
Molecular Pharmacology|August 19, 2007
Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin IIAnnie Quan, Andrew B McGeachie, Damien J Keating, et al.
The Journal of Cell Biology|December 13, 2006
Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanismHélène Pelicano, Rui-Hua Xu, Min Du, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patientsC L Shapiro, L Ayash, I J Webb, et al.
The American Journal of Medicine|May 1, 1986
Acute promyelocytic leukemia. M.D. Anderson Hospital experienceH M Kantarjian, M J Keating, R S Walters, et al.
Oncogene|April 12, 2016
Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexilineP-P Liu, J Liu, W-Q Jiang, et al.
Blood|February 15, 2003
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemiaHelen McCarthy, William G Wierda, Lynn L Barron, et al.
British Journal of Haematology|May 20, 2003
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expressionFrancis J Giles, B Nebiyou Bekele, Susan O'Brien, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1990
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemiaB D Cheson, P A Cassileth, D R Head, et al.
Pageof 112